 Anglo-Swedish drug has closed down 8% in UK trade after failure of its Iressa drug in clinical trial . The lung cancer drug did not significantly prolong survival in patients with the disease . This setback follows the rejection by the US in October of its anti-coagulant pill Exanta . Another of its major money spinners - cholesterol drug Crestor - is facing mounting safety concerns . AztraZeneca has now appointed a new executive director to the board . John Patterson will be in charge of drug development .